bluebird bio has hit a major milestone, garnering U.S. Food and Drug Administration approval to market its first product in the U.S., which is also its first cell therapy designed to treat cancer.
Read More
Drugmaker Bristol-Myers Squibb announced Thursday a $74 billion deal to buy Celgene, in one of the biggest mergers in pharmaceutical industry history.
Read MoreThe two companies will team up on TARGET-IBD, a longitudinal observational study that evaluates patients with inflammatory bowel disease, including adult and pediatric patients with ulcerative colitis, Crohn’s disease and indeterminate colitis.
Read More
